DNA amplification was carried out on the samples using the polymerase chain reaction, with the P carinii specific primers pAZ102-H and pAZ102-E.1 2 The amplification reaction mixture contained 50 mM potassium chloride, 10 mM Tris, pH 9 0, 01% Triton X-100, 3 mM magnesium chloride, 400 RM dNTPs (each of the four deoxyribonucleoside triphosphates, Boehringer Mannheim), 1 ,uM oligonucleotide primer and 0-025 units/pI of Taq polymerase (Promega), with denaturation at 940C for 1-5 min, annealing at 55°C for 1-5 min, and extension at 720C for 2X0 min for 40 cycles. Negative controls, with no added template, were tested with each clinical sample. The amplification products underwent electrophoretic separation in 1X5% agarose gels, and the presence of a P carinii specific band (346 base pairs) was detected by visualisation with ultraviolet light after ethidium bromide staining.
The diagnosis of Pneumocystis carinii pneumonia in childhood has, in the past, usually depended on bronchoscopic or non-bronchoscopic alveolar lavage to identify P carinii by histochemical staining in the lower airway secretions. The technique of polymerase chain reaction has been shown to detect P carinii DNA effectively in upper airway secretions of infected adult patients.1 2 We describe the use of polymerase chain reaction in the detection of P 
Results
The polymerase chain reaction was carried out on total DNA extracted from the nasopharyngeal secretions from each patient and resulted in the synthesis of a P carinii specific amplification product, detected on ethidium bromide stained gels. Only 50 RI of secretions were required for this test. The detection of P carinii DNA allowed the non-invasive confirmation of the clinical diagnosis of P carinii pneumonia. However, in one infant (patient 1) who required ventilation, P carinii was also identified by microscopy after methamine silver staining of a sample of bronchoscopic lavage fluid. The three patients responded to high dose intravenous co-trimoxazole, in a manner consistent with the diagnosis of P carinii pneumonia. polymerase chain reaction showed P carinii DNA to be present in their nasopharyngeal secretions. It is increasingly recognised that lower airway infection with P carinii is accompanied by the presence of the organism in upper airway secretions.3 Access to lower airway secretions may be limited in children whose clinical state does not warrant intubation and ventilation. Bronchoscopic lavage may lead to respiratory deterioration in a patient already in respiratory distress. The alternative of induced sputum is impractical in infants and young children. Therefore, identification of P carinii in nasopharyngeal secretions may provide a simple and noninvasive means of diagnosis. A case report has previously described the identification of P carinii, using a fluorescent antibody technique, in the nasopharyngeal secretions of an HIV positive infant who had signs consistent with P carinii pneumonia.4
Methods
The polymerase chain reaction technique is highly specific and sensitive for P carinii DNA and has been shown to be diagnostically useful in bronchoalveolar lavage and induced sputum samples in adults with pneumonia.1 2 Combining the sensitivity and specificity of P carinii DNA detection by the polymerase chain reaction with this non-invasive sample method offers a potentially valuable diagnostic tool that needs to be evaluated in a large group of children with suspected P carinii pneumonia.
None of the infants was on prophylactic co-trimoxazole at presentation. The current AML regimen does not prescribe it, nor is it included until week 16 of the current MRC-UKALL infant protocol once the late intensification has been completed, on the basis of the small risk to patients. The occurrence of pneumocystis pneumonia in infants early in their chemotherapy regimen suggests that infants with leukaemia are at particular risk of P carinii pneumonia and should therefore receive prophylactic co-trimoxazole early in their treatment. 
